Vyleesi Side-Effect Reports From Real Users: What the Data Actually Shows
HealthRX.com
Nausea is the most reported Vyleesi side effect
Key numbers
- 40.0%Women on Vyleesi reporting nausea in the placebo-controlled trials, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 21%Patients with nausea after the first dose, falling to about 3% after later dosesSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 18%Trial participants who stopped Vyleesi because of adverse reactions, versus 2% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Bremelanotide (Vyleesi) side effects in human trial data
Kingsberg 2019, a randomized controlled trial of 1,247 women, found more nausea, flushing and headache with bremelanotide than placebo, at 10% or more. Simon 2019, an open-label extension of 684 women, reported nausea (40.4%), flushing (20.6%) and headache (12.0%) as the most common related events.
| Measure | Value | Note |
|---|---|---|
| Human: Kingsberg 2019, randomized controlled trial, 1,247 in safety population | nausea, flushing, headache 10% or more | Bremelanotide had more nausea, flushing and headache than placebo, at 10% or more in both studies. PMID 31599840 |
| Human: Kingsberg 2019, adverse event severity | most mild or moderate | The majority of treatment-emergent adverse events were mild or moderate in intensity. PMID 31599840 |
| Human: Simon 2019, open-label extension, 684 women from core trials | nausea most common side effect | Nausea (40.4%), flushing (20.6%), and headache (12.0%) were the most common related events. PMID 31599847 |
How this was calculated
PubMed title and abstract search on 2026-11-13 for bremelanotide, Vyleesi, PT-141 with adverse event, adverse reaction, side effect, adverse effect: 6 records, 3 abstracts read, 2 studies listed in 3 rows, each row summarising its own abstract.
Bremelanotide (Vyleesi) reported side effects: 2 human, 0 animal and 0 laboratory studies of 6 PubMed records.
See the public record for Bremelanotide
At a glance
- Drug / bremelanotide 1.75 mg subcutaneous autoinjector (Vyleesi)
- Most-reported side effect / nausea, 40.0% vs 1.3% on placebo [1]
- Next most common / flushing 20.3%, injection-site reactions 13.2%, headache 11.3% [1]
- Stopped the trials over side effects / 18% on Vyleesi vs 2% on placebo; nausea alone 8% [1]
- Nausea timing / median onset within 1 hour of the dose, lasting about 2 hours [1]
- Blood pressure / maximal rise of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose [1]
- Contraindicated in / uncontrolled hypertension or known cardiovascular disease [1]
What the reported rates actually are
The largest set of patient-reported side-effect data for bremelanotide comes from two identical 24-week placebo-controlled trials: 1,247 premenopausal women with acquired, generalized hypoactive sexual desire disorder, 627 on Vyleesi 1.75 mg as needed and 620 on placebo [1]. The label lists every reaction reported by at least 2% of women on the drug and more often than on placebo [1]:
- Nausea: 40.0% vs 1.3%
- Flushing: 20.3% vs 0.3%
- Injection-site reactions (pain, redness, hematoma, itching, bleeding, bruising, tingling, numbness): 13.2% vs 8.4%
- Headache: 11.3% vs 1.9%
- Vomiting: 4.8% vs 0.2%
- Cough: 3.3% vs 1.3%
- Fatigue: 3.2% vs 0.5%
- Hot flush: 2.7% vs 0.2%
- Paresthesia: 2.6% vs 0.0%
- Dizziness: 2.2% vs 0.5%
- Nasal congestion: 2.1% vs 0.5%
Most events were mild (31%) or moderate (40%) in intensity and transient [1]. Serious adverse reactions were reported in 1.1% of women on Vyleesi and 0.5% on placebo [1]. The label notes that adverse-reaction rates from clinical trials cannot be directly compared with rates from another drug's trials and may not reflect rates in practice [1]. The rates on this page come from these trials and the label, not from forum or review-site posts.
Nausea: how often, how long, and does it fade
Nausea was the most commonly reported adverse reaction in the placebo-controlled trials, affecting 40.0% of women taking Vyleesi versus 1.3% taking placebo [1]. The label reports that 13% of Vyleesi-treated patients received an anti-nausea medicine and 8% stopped the trials because of nausea, versus no placebo-treated patients who stopped for that reason [1]. The median onset was within one hour of the dose and it lasted about two hours [1].
Nausea was highest after the first dose, reported in 21% of patients, then declined to about 3% after subsequent doses, and the label states that nausea improves for most patients with the second dose [1]. For women who remain bothered, the label says to consider discontinuing Vyleesi for persistent or severe nausea, or starting anti-nausea treatment for those who want to continue [1].
Longer-term data point the same way. In the 52-week open-label extension, 684 women received Vyleesi after completing the double-blind phase, and the treatment-emergent events considered drug-related were nausea in 40.4%, flushing in 20.6% and headache in 12.0%; the only severe event experienced by more than one participant across both studies was nausea [2]. That extension had no placebo group, so its numbers describe what happened over a year, not how much of it the drug caused [2].
What people on Reddit report
Accounts from Vyleesi users on Reddit about how their own doses went, including people with no nausea, people with long-lasting leg or arousal effects, and people who vomited or had headaches.
I'm happy to say I did not experience nausea. My tummy felt a little weird about 15 minutes after injection, but it went away, and I was able to eat and function normally all day.Read the source discussion
My legs felt incredibly weird after taking it, and it took almost a whole day for the feeling to go away. Hated it.Read the source discussion
I tried it twice and someone else reported this side effect too but it was the arousal that came in waves combined with restless legs and it lasted for hours. It was quite unpleasant.Read the source discussion
The first time i used it, it was great! The second time, not so great. I vomited so hard it made my throat bleed a little and then the stuffy nose, headache and chills that followed were wicked.Read the source discussion
after injecting herself the first time, she became nauseous for about an hour, and then had a headache and a red face for hours.Read the source discussion
Questions worth asking
Anti-nausea pills taken beforehand did not help
A common assumption is that taking ondansetron before the injection prevents Vyleesi nausea. A phase 4, single-dose, placebo-controlled study tested exactly that: 228 healthy women were randomized 1:1 to 8 mg oral ondansetron or placebo 30 minutes before a single 1.75 mg subcutaneous dose of Vyleesi, and there was no significant difference in the incidence of nausea between groups [1]. The label therefore states that pre-treatment with oral ondansetron 30 minutes before Vyleesi does not reduce nausea and is not recommended [1]. It also notes that ondansetron given after Vyleesi, or after nausea has started, has not been formally studied [1].
Flushing, headache and injection sites
Flushing affected 20.3% of women on Vyleesi versus 0.3% on placebo [1]. None of the flushing events were serious, few were severe (under 1%), and 1% of patients stopped the study because of flushing [1].
Headache affected 11.3% versus 1.9% on placebo [1]. One patient had a serious headache (intractable pain leading to hospitalization), and 1% of patients discontinued the study because of headache [1].
Injection-site reactions as a group affected 13.2% versus 8.4% on placebo [1]. The label groups pain, unspecified reactions, redness, hematoma, itching, bleeding, bruising, tingling and numbness under that single figure rather than reporting them separately [1].
Skin darkening (focal hyperpigmentation)
In the placebo-controlled trials, 1% of patients receiving up to 8 doses a month developed focal hyperpigmentation, including the face, gums and breasts, compared with no placebo-treated patients [1]. Frequency depends heavily on dosing schedule: in another study, 38% of patients developed focal hyperpigmentation after daily dosing for 8 days, and an additional 14% developed new pigmentary changes after 8 more consecutive days [1]. Patients with dark skin were more likely to develop it, and resolution was not confirmed in all patients after the drug was stopped [1]. The label says to consider discontinuing Vyleesi if hyperpigmentation develops [1].
Blood pressure and heart rate
Each dose produces a short rise in blood pressure and a small drop in heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours, and no additive effect appeared with repeat daily dosing 24 hours apart for up to 16 days [1]. Those are maximal, not average, figures.
The averages come from a separate open-label ambulatory monitoring study of 127 premenopausal women dosed once daily for 8 days: mean daytime blood pressure rose 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1]. The mean peak effect was 2.8 mmHg systolic at 4 to 8 hours and 2.7 mmHg diastolic at 0 to 4 hours post-dose, and readings 12 to 24 hours later were similar to pre-dose values [1].
Vyleesi is contraindicated in women with uncontrolled hypertension or known cardiovascular disease, and it is not recommended for patients at high risk of cardiovascular disease [1]. The label says to consider cardiovascular risk and make sure blood pressure is well controlled before starting and periodically during treatment [1].
Why so many women stop
Discontinuation because of adverse reactions was 18% on Vyleesi versus 2% on placebo [1]. The specific reasons on Vyleesi were nausea 8%, headache 2%, vomiting 1%, flushing 1%, injection-site reactions 1%, flu-like symptoms under 1% and increased blood pressure under 1% [1].
Overall dropout from the double-blind phase was higher than the adverse-reaction figure alone: 40% versus 13% in study 1 and 39% versus 25% in study 2 [1].
For comparison, on the Female Sexual Function Index desire domain, bremelanotide improved scores by 0.30 points in study 301 and 0.42 in study 302 versus placebo (integrated 0.35, all P<0.001) [3]. Desire-related distress fell by 0.37, 0.29 and 0.33 points versus placebo (P<0.001, P=0.005, P<0.001) [3]. The trials found no significant difference in the number of satisfying sexual events [3].
Vyleesi is not the same product as peptides sold as PT-141
All of the rates on this page describe Vyleesi, the FDA-approved bremelanotide product, a 1.75 mg prefilled autoinjector available by prescription [1]. Products sold as PT-141 for research use or as compounded peptides are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [4]. Side-effect figures from the Vyleesi trials do not describe those products.
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
How bad is the nausea with Vyleesi?
Does the nausea get better with repeated doses?
Does ondansetron prevent Vyleesi nausea?
Does Vyleesi raise blood pressure?
Can Vyleesi cause lasting skin darkening?
How long does Vyleesi stay in the body?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What are the common side effects of Vyleesi?
The most common are nausea (40.0% vs 1.3% on placebo), flushing (20.3% vs 0.3%), injection-site reactions (13.2% vs 8.4%) and headache (11.3% vs 1.9%). Vomiting, cough, fatigue and hot flush were less common but still more frequent than on placebo.
How do I know if Vyleesi is working?
The data given do not show how to tell whether Vyleesi is working for an individual. In the trials, scores on the Female Sexual Function Index desire domain improved by 0.30 points in study 301 and 0.42 in study 302 versus placebo, but there was no significant difference in the number of satisfying sexual events.
What are people saying about Vyleesi in reviews?
The rates here come from the clinical trials and the label, not from forum or review-site posts, so they do not summarize what reviewers say about Vyleesi.
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- Federal Register public inspection document 2026-22192.
- Reddit participants. Vyleesi User Review (r/Menopause). Accessed 2026-11-11.
- Reddit participants. Vyleesi (r/Menopause). Accessed 2026-11-11.
- Reddit participants. Vyleesi Reactions (r/DeadBedrooms). Accessed 2026-11-11.